Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care Setting

Table 2

List of OADs mentioned in the NKF guidelines.

Therapeutic Class	Medication
Second-generation; sulfonylureas	Glyburide, glipizide, glimepiride
Alpha-glucosidase inhibitors	Acarbose, miglitol
Biguanides	Metformin
Meglitinides	Repaglinide, nateglinide
Thiazolidinediones	Rosiglitazone, pioglitazone
DPP-4 inhibitors^‡	Sitagliptin

DPP-4: Dipeptidyl peptidase inhibitor-4
^‡Saxagliptin and linagliptin were not included in the NKF guideline.
They were included in the PI concordance assessment.